IPX203 is an investigational product containing CD-LD.
IPX203-B16-01 Study Design:
A randomized, open-label, rater-blinded, multicenter, 2-treatment, 2-period, multiple-dose crossover study.
Approximately 30 qualified IR CD-LD-experienced advanced PD subjects will be randomized.
The study duration will be approximately 8 weeks, including the screening period.
